Literature DB >> 18055578

Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival.

Marc-Michael Zaruba1, Bruno C Huber, Stefan Brunner, Elisabeth Deindl, Robert David, Rebekka Fischer, Gerald Assmann, Nadja Herbach, Sebastian Grundmann, Ruediger Wanke, Josef Mueller-Hoecker, Wolfgang-Michael Franz.   

Abstract

AIMS: An ongoing concept is that stem cells have the potential to regenerate the injured myocardium. In addition to direct vasorelaxing effects on the vasculature, which are mediated by an increased cAMP production leading to a decreased calcium influx in smooth muscle cells, parathyroid hormone (PTH) was recently shown to facilitate stem cell mobilization. Therefore, we analysed in a murine model of experimental myocardial infarction (MI) the influence of PTH treatment on survival, functional parameters, stem cell migration, and expression of vascular endothelial growth factor A (VEGF-A). METHODS AND
RESULTS: Mice (C57BL/6) were treated with PTH (80 microg/kg/d) for up to 14 days after coronary artery ligation. Functional and immunohistochemical analyses were performed at days 6 and 30 after MI. Stem cells and VEGF expression in the myocardium were analysed by FACS and qRT-PCR at day 2 after MI. PTH-treated animals revealed a significant improvement of post-MI survival and myocardial function that was related to a subsequent reduction of left ventricular wall thinning and scar extension. Infarcted hearts of PTH-treated mice revealed increased numbers of CD45(+)/CD34(+) progenitor cells as well as an upregulation of VEGF-A mRNA associated with increased neovascularization and cell survival.
CONCLUSIONS: PTH application after MI increases migration of angiogenic CD45(+)/CD34(+) progenitor cells to the ischaemic heart, which may attenuate ischaemic cardiomyopathy. As PTH is already used in patients with osteoporosis, our findings may have a direct impact on the initiation of clinical studies in patients with ischaemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055578     DOI: 10.1093/cvr/cvm080

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  22 in total

1.  Promises and pitfalls in cell replacement therapy for heart failure.

Authors:  Markus Krane; Oliver Wernet; Sean M Wu
Journal:  Drug Discov Today Dis Mech       Date:  2010

2.  Understanding estrogen action during menopause.

Authors:  Jameel Iqbal; Mone Zaidi
Journal:  Endocrinology       Date:  2009-08       Impact factor: 4.736

3.  In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [⁶⁸Ga]Annexin A5 and [¹⁸F]FDG PET.

Authors:  Andrei Todica; Mathias J Zacherl; Hao Wang; Guido Böning; Nathalie L Jansen; Carmen Wängler; Peter Bartenstein; Michael C Kreissl; Marcus Hacker; Stefan Brunner; Sebastian Lehner
Journal:  J Nucl Cardiol       Date:  2014-09-05       Impact factor: 5.952

4.  FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following Sitagliptin + G-CSF therapy after acute myocardial infarction.

Authors:  Lisa Gross; Lisa Paintmayer; Sebastian Lehner; Lydia Brandl; Christoph Brenner; Ulrich Grabmaier; Bruno Huber; Peter Bartenstein; Hans-Diogenes Theiss; Wolfgang-Michael Franz; Steffen Massberg; Andrei Todica; Stefan Brunner
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-09-28       Impact factor: 6.875

Review 5.  Impact of parathyroid hormone on bone marrow-derived stem cell mobilization and migration.

Authors:  Bruno C Huber; Ulrich Grabmaier; Stefan Brunner
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

6.  Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik.

Authors:  A J van Ballegooijen; M Visser; M F Cotch; A E Arai; M Garcia; T B Harris; L J Launer; G Eiríksdóttir; V Gudnason; I A Brouwer
Journal:  J Clin Endocrinol Metab       Date:  2013-04-12       Impact factor: 5.958

7.  Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats.

Authors:  Sanela Smajilovic; Rasmus Schaal-Jensen; Reza Jabbari; Una Smajilovic; Stig Haunso; Jacob Tfelt-Hansen
Journal:  Open Cardiovasc Med J       Date:  2010-03-31

8.  Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6.

Authors:  Flavia Q Pirih; Megan N Michalski; Sun W Cho; Amy J Koh; Janice E Berry; Eduardo Ghaname; Pachiyappan Kamarajan; Edith Bonnelye; Charles W Ross; Yvonne L Kapila; Pierre Jurdic; Laurie K McCauley
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

9.  Parathyroid hormone accelerates decompensation following left ventricular hypertrophy.

Authors:  Hyeseon Cha; Hyeon Joo Jeong; Seung Pil Jang; Joo Yeon Kim; Dong Kwon Yang; Jae Gyun Oh; Woo Jin Park
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

10.  [68Ga]-albumin-PET in the monitoring of left ventricular function in murine models of ischemic and dilated cardiomyopathy: comparison with cardiac MRI.

Authors:  Andrei Todica; Stefan Brunner; Guido Böning; Sebastian Lehner; Stephan G Nekolla; Moritz Wildgruber; Christopher Übleis; Carmen Wängler; Martina Sauter; Karin Klingel; Paul Cumming; Peter Bartenstein; Ralf Schirrmacher; Wolfgang Michael Franz; Marcus Hacker
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.